Antibody-Mediated Graft Rejection Market Anticipating Remarkable Growth by 2032, Insights by DelveInsight CSL Behring (Clazakizumab), Hansa Biopharma (Imlifidase), Sanofi (BIVV020), Viela Bio (VIB4920)

As per DelveInsight, the Antibody-Mediated Graft Rejection Market is anticipated to evolve immensely in the coming years owing to the increase in R&D activity, increasing population, growing awareness, improved management, and better outcomes with the emerging therapies.

DelveInsight's "Antibody-Mediated Graft Rejection Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Antibody-Mediated Graft Rejection Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Antibody-Mediated Graft Rejection therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Antibody-Mediated Graft Rejection treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Antibody-Mediated Graft Rejection: An Overview
Antibody‐mediated rejection (AMR) is a significant complication following kidney transplantation that contributes toward both short‐ and long‐term injury in transplant recipients. Despite the use of desensitization protocols, up to one‐third of highly sensitized recipients may develop acute AMR following transplantation. AMR is also of significant concern in nonsensitized individuals, as de novo DSAs can develop early or late after transplantation.

AMR often represents a pathological spectrum that co-exists with T-cell-mediated rejection. Active (acute) AMR is characterized by serological evidence of donor specific antibody (DSA), peritubular capillaritis, glomerulitis, cellular necrosis, thrombotic microangiopathy, and a relatively rapid decline in allograft function. The response to currently available therapies is often favorable. Chronic AMR, on the other hand, is characterized by transplant glomerulopathy, a distinct pathophysiological process resulting from a repetitive pattern of thrombotic events and inflammatory changes that lead to endothelial cell injury and allograft matrix remodeling. It usually results in a slow and progressive decline in renal function, unlikely to be reversed by current therapeutic strategies.

Despite the use of advanced techniques for the detection of human leukocyte antigen (HLA) or non-HLA donor-specific antibodies, the alloimmune response remains an important barrier for successful long-term allograft function. Treatment of AMR with currently available therapies has produced various results, some of them suboptimal, precluding the development of standardized protocols. New therapies are promising, but randomized controlled trials are needed to find surrogate markers and improve the efficacy of therapy.

Antibody-Mediated Graft Rejection Market Key Facts
• According to Organ Donor Statistics (2022), 24,670 patients received kidney transplants; 9,236 liver transplants; 3,817 heart transplants; and 2,524 lung transplants.
• According to Cabezas et al. (2022), AMR is a significant complication following kidney transplantation that contributes towards short- and long-term injury in ~1-10% of kidney-transplant recipients and increases the risk of graft loss in France.
• As per Stewart (2021), the number of living and deceased heart transplants in Italy fluctuated significantly throughout the period from 2007 to 2020. In 2021, 251 heart transplants were performed.
• According to Tatapudi and Lonze (2017), AMR is estimated to occur in 3-10% of transplant recipients, and it represents 20-30% of episodes of acute rejection in the US.
• According to the National Institute of Diabetes and Digestive and Kidney Diseases, a total of 22,817 kidney transplants were completed in the United States in 2020, whereas in 2021 90,201 transplants were planned.

Discover How the Antibody-Mediated Graft Rejection Market Will Grow by 2032:
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Antibody-Mediated Graft Rejection Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Antibody-Mediated Graft Rejection therapies in the market. It also provides a detailed assessment of the Antibody-Mediated Graft Rejection market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Antibody-Mediated Graft Rejection drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Antibody-Mediated Graft Rejection Epidemiology
The epidemiology section covers detailed insights into the historical, and current Antibody-Mediated Graft Rejection patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Antibody-Mediated Graft Rejection Epidemiology Segmented as -
• Transplant Incidence cases [2019-2032]
• Antibody-mediated Rejection Cases [2019-2032]

Get Key Insights Into the Evolving Antibody-Mediated Graft Rejection Epidemiology Trends @
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Antibody-Mediated Graft Rejection Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antibody-Mediated Graft Rejection market or expected to be launched during the study period. The analysis covers the market share by Antibody-Mediated Graft Rejection drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Antibody-Mediated Graft Rejection Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Antibody-Mediated Graft Rejection Therapeutics Assessment
Treatment for AMR is not standardized, and there is still no evidence-based treatment guidelines. A recent therapy of AMR in renal allografts is systematically reviewed by Wan et al. (n.d.). In addition to plasma exchange and intravenous immunoglobulin, which still present a backbone of treatment, several other therapies have been tried in small studies without consistent benefit, including anti-CD20, proteasome inhibitors, complement inhibitors, anti-interleukin-6 receptor blockers, and immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS).

Leading Companies in the Antibody-Mediated Graft Rejection Therapeutics Market Include
• CSL Behring
• Hansa Biopharma
• Sanofi
• Viela Bio
And Many More

Emerging and Marketed Antibody-Mediated Graft Rejection Therapies Covered in the Report Include
• Clazakizumab: CSL Behring
• Imlifidase: Hansa Biopharma
• BIVV020: Sanofi
• VIB4920: Viela Bio
And Many Others

Learn More About the Emerging Therapies & Key Companies in the Antibody-Mediated Graft Rejection Therapeutics Market:
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Antibody-Mediated Graft Rejection Competitive Intelligence Analysis
4. Antibody-Mediated Graft Rejection Market Overview at a Glance
5. Antibody-Mediated Graft Rejection Background and Overview
6. Antibody-Mediated Graft Rejection Patient Journey
7. Antibody-Mediated Graft Rejection Epidemiology and Patient Population
8. Antibody-Mediated Graft Rejection Treatment Algorithm, Current Treatment, and Medical Practices
9. Antibody-Mediated Graft Rejection Unmet Needs
10. Key Endpoints of Antibody-Mediated Graft Rejection Treatment
11. Antibody-Mediated Graft Rejection Marketed Products
12. Antibody-Mediated Graft Rejection Emerging Therapies
13. Antibody-Mediated Graft Rejection Seven Major Market Analysis
14. Attribute Analysis
15. Antibody-Mediated Graft Rejection Market Outlook (7 major markets)
16. Antibody-Mediated Graft Rejection Access and Reimbursement Overview
17. KOL Views on the Antibody-Mediated Graft Rejection Market.
18. Antibody-Mediated Graft Rejection Market Drivers
19. Antibody-Mediated Graft Rejection Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market

Lipodystrophy Market
https://www.delveinsight.com/report-store/lipodystrophy-market

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market

Anaplastic Astrocytoma Market
https://www.delveinsight.com/report-store/anaplastic-astrocytoma-market

Singapore Healthcare Outlook
https://www.delveinsight.com/report-store/singapore-healthcare-outlook-report

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

Chronic Idiopathic Constipation Market
https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-market

Hay Fever Conjunctivitis Market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market

Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

Cerebral Infarction Market
https://www.delveinsight.com/report-store/cerebral-infarction-market

CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market

Hernia Repair Devices Market
https://www.delveinsight.com/report-store/hernia-repair-devices-market

Bronchial Hyperreactivity Market
https://www.delveinsight.com/report-store/bronchial-hyperreactivity-market

Chronic Focal Epilepsy Market
https://www.delveinsight.com/report-store/chronic-focal-epilepsy-market

Dental Lasers Market
https://www.delveinsight.com/report-store/dental-lasers-market

Down Syndrome Market
https://www.delveinsight.com/report-store/down-syndrome-market

Extracorporeal Circulation System Market
https://www.delveinsight.com/report-store/extracorporeal-circulation-system-market

Failed Back Surgery Syndrome Market
https://www.delveinsight.com/report-store/failed-back-surgery-syndrome-market

Germ Cell Tumor Market
https://www.delveinsight.com/report-store/germ-cell-tumor-market

Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market

India Healthcare Outlook
https://www.delveinsight.com/report-store/india-healthcare-outlook-report

Insulin Glargine Biosimilar
https://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market

Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market

Nasolabial Fold Market
https://www.delveinsight.com/report-store/nasolabial-fold-market

Neuroleptic Malignant Syndrome Market
https://www.delveinsight.com/report-store/neuroleptic-malignant-syndrome-market

Pachyonychia Congenita Market
https://www.delveinsight.com/report-store/pachyonychia-congenita-market

Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market

Reactive Airway Disease Market
https://www.delveinsight.com/report-store/reactive-airway-disease-market

Seborrhea Market
https://www.delveinsight.com/report-store/seborrhea-market

Substance (Drug) Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market

Synchronous Endometrial and Ovarian Cancer (SEOC) Market
https://www.delveinsight.com/report-store/synchronous-endometrial-and-ovarian-cancer-seoc-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Urinary Tract Infection Devices Market
https://www.delveinsight.com/report-store/urinary-tract-infection-devices-market

Varicose Veins Market
https://www.delveinsight.com/report-store/varicose-veins-market

Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.